Skip to main content
main-content

18.01.2017 | Onkologie | Onlineartikel

Anti-angiogenesis with nintedanib: activity in mesothelioma, and potential biomarkers

Figure: LUME-Meso: PFS with nintedanib or placebo in addition to standard chemotherapy in patients with malignant pleural mesothelioma

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten